Savara | Jotup

Savara Announces New Employment Inducement Grant

Retrieved on:

Friday, March 22, 2024

Biotechnology, Pharmaceutical, Health, Clinical Trials, Savara, Employment, Inc.

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees.

Key Points:

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees.
On March 21, 2024, Savara's Board of Directors granted the inducement awards to two new employees who recently joined the Company.
These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules as an inducement material to the employees’ acceptance of employment with the Company.
The options have an exercise price of $4.89 per share, the closing trading price of the Company's common stock on the NASDAQ Global Market on the grant date.

Savara Announces New Employment Inducement Grant

Retrieved on:

Friday, December 15, 2023

Biotechnology, Pharmaceutical, Health, Clinical Trials, RSU, Employment, Inc., Compensated emancipation, Savara

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee.

Key Points:

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to a new employee.
On December 11, 2023, the Compensation Committee of Savara's Board of Directors granted the inducement awards to a new employee who recently joined the Company.
These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules as an inducement material to the employee’s acceptance of employment with the Company.
The RSUs vest in full on the two-year anniversary of the employee’s first day of employment, subject to the employee’s continued employment on such vesting date.

Savara Reports Third Quarter Financial Results and Provides Business Update

Retrieved on:

Thursday, November 9, 2023

Biotechnology, Pharmaceutical, Health, Clinical Trials, Investment, Disease, Chemistry, Inc., Pulmonology, Research, APAP, Chair, Fine chemical, Savara

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third quarter ending September 30, 2023 and provided a business update.

Key Points:

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the third quarter ending September 30, 2023 and provided a business update.
“We remain on track to report top line data from the pivotal, Phase 3 IMPALA-2 trial by the end of the second quarter 2024,” said Matt Pauls, Chair and CEO, Savara.
“In parallel, we are working to provide pulmonologists in the U.S. and Europe with a simple, accurate, no-cost, laboratory-based antibody blood test for aPAP.
As of September 30, 2023, the Company had cash, cash equivalents and short-term investments of ~$168.3 million and debt of ~$26.3 million.

Savara Announces New Employment Inducement Grant

Retrieved on:

Friday, October 6, 2023

Health, Medical Devices, Other Science, Clinical Trials, Science, Pharmaceutical, Biotechnology, Inc., Employment, RSU, Compensated emancipation, Pharmaceutical industry, Savara

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to three new employees.

Key Points:

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to three new employees.
On October 3, 2023, the Compensation Committee of Savara's Board of Directors granted the inducement awards to three new employees who recently joined the Company.
These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules as an inducement material to the employees’ acceptance of employment with the Company.
The RSUs vest in full on the two-year anniversary of the employee’s first day of employment, subject to the employee’s continued employment on such vesting date.

Soleno Therapeutics Announces Appointment of Industry Veteran Matthew Pauls, J.D., M.B.A. to Board of Directors

Retrieved on:

Wednesday, August 16, 2023

Prader–Willi syndrome, IPO, Therapy, Senior, Chief commercial officer, Bristol Myers Squibb, Shire (pharmaceutical company), Patient, Michigan State University College of Law, M.B.A, Commercial, Johnson & Johnson, Rare, PWS, Central Michigan University, Management, Insming, Savara

REDWOOD CITY, Calif., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of Matthew Pauls, J.D., M.B.A, to its Board of Directors, effective August 15, 2023.

Key Points:

REDWOOD CITY, Calif., Aug. 16, 2023 (GLOBE NEWSWIRE) -- Soleno Therapeutics, Inc. (Soleno) (NASDAQ: SLNO), a clinical-stage biopharmaceutical company developing novel therapeutics for the treatment of rare diseases, today announced the appointment of Matthew Pauls, J.D., M.B.A, to its Board of Directors, effective August 15, 2023.
Mr. Pauls is an accomplished industry veteran with extensive executive leadership, strategic and commercial experience.
“Matt is a highly accomplished biopharmaceutical executive, and we are pleased to welcome him to the Board,” said Ernest Mario, Ph.D., Chairman of the Board of Directors of Soleno.
In addition to his Board positions at Savara and Strongbridge, Mr. Pauls has also served as Chair of the Board of Directors of Mast Therapeutics and was a member of the Board of Directors of Zyla Life Sciences.

Savara Reports Second Quarter Financial Results and Provides Business Update

Retrieved on:

Thursday, August 10, 2023

Biotechnology, Pharmaceutical, Health, Clinical Trials, Chemistry, Inc., Research, Patient, Investment, Chair, Cryptocurrency, Savara

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the second quarter ending June 30, 2023 and provided a business update.

Key Points:

Savara Inc. (Nasdaq: SVRA) (the Company), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the second quarter ending June 30, 2023 and provided a business update.
“The Company continues to make strong progress with the molgramostim development program,” said Matt Pauls, Chair and CEO, Savara.
The increase is due to the hiring of additional personnel for key positions in the first quarter and related costs to facilitate the management of our business and operations.
As of June 30, 2023, the Company had cash, cash equivalents and short-term investments of ~$105.2 million and debt of ~$26.2 million.

Savara Announces New Employment Inducement Grant

Retrieved on:

Friday, August 4, 2023

Biotechnology, Pharmaceutical, Human Resources, General Health, Health, Professional Services, Clinical Trials, Other Health, Inc., Employment, Compensated emancipation, Pharmaceutical industry, Savara

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to three new employees.

Key Points:

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to three new employees.
On August 3, 2023, the Compensation Committee of Savara's Board of Directors granted the inducement awards to three new employees who recently joined the Company.
The inducement awards consist of options to purchase an aggregate of 150,000 shares of the Company’s common stock.
These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules as an inducement material to the employees’ acceptance of employment with the Company.

Savara Announces Pricing of $80 Million Underwritten Offering of Common Stock and Pre-Funded Warrants

Retrieved on:

Thursday, July 13, 2023

All of the securities to be sold in the offering are being sold by Savara.

Key Points:

All of the securities to be sold in the offering are being sold by Savara.
The offering is expected to close on July 17, 2023, subject to the satisfaction of customary closing conditions.
Oppenheimer & Co. Inc. is acting as the co-lead manager and H.C. Wainwright & Co., LLC is acting as co-manager for the offering.
An electronic copy of the prospectus supplement and accompanying prospectus relating to the offering will be available on the SEC website at www.sec.gov .

Savara Reports First Quarter Financial Results and Provides Business Update

Retrieved on:

Monday, May 15, 2023

Biotechnology, Medical Devices, Health, Pharmaceutical, Clinical Trials, Chemistry, Inc., Research, Investment, Safety, Chair, Fine chemical, Cryptocurrency, Savara

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending March 31, 2023 and provided a business update.

Key Points:

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, reported financial results for the first quarter ending March 31, 2023 and provided a business update.
Research and development expenses increased by $3.1 million, or 53.7%, to $8.7 million for the three months ended March 31, 2023 from $5.7 million for the three months ended March 31, 2022.
The increase was primarily attributable to the strategic addition of personnel and related costs for key positions to facilitate the management of our business and operations.
As of March 31, 2023, the Company had cash, cash equivalents and short-term investments of $114.8 million.

Savara Announces New Employment Inducement Grant

Retrieved on:

Friday, May 5, 2023

Biotechnology, Pharmaceutical, Health, Inc., Employment, RSU, Compensated emancipation, Pharmaceutical industry, Savara

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees.

Key Points:

Savara Inc. (Nasdaq: SVRA), a clinical stage biopharmaceutical company focused on rare respiratory diseases, today announced the grant of inducement awards to two new employees.
On May 3, 2023, the Compensation Committee of Savara's Board of Directors granted the inducement awards to two new employees who recently joined the Company.
These equity awards were granted under the Savara Inc. 2021 Inducement Equity Incentive Plan pursuant to Rule 5635(c)(4) of the NASDAQ Listing Rules as an inducement material to the employees’ acceptance of employment with the Company.
The RSUs vest in full on the two-year anniversary of the employee’s first day of employment, subject to the employee’s continued employment on such vesting date.